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background
 
Despite the prevalence of multidrug-resistant tuberculosis in nearly all low-income
countries surveyed, effective therapy has been deemed too expensive and considered
not to be feasible outside referral centers. We evaluated the results of community-
based therapy for multidrug-resistant tuberculosis in a poor section of Lima, Peru.
 
methods
 
We describe the first 75 patients to receive ambulatory treatment with individualized
regimens for chronic multidrug-resistant tuberculosis in northern Lima. We conduct-
ed a retrospective review of the charts of all patients enrolled in the program between
August 1, 1996, and February 1, 1999, and identified predictors of poor outcomes.
 
results
 
The infecting strains of 
 
Mycobacterium tuberculosis
 
 were resistant to a median of six
drugs. Among the 66 patients who completed four or more months of therapy, 83 per-
cent (55) were probably cured at the completion of treatment. Five of these 66 patients
(8 percent) died while receiving therapy. Only one patient continued to have positive
cultures after six months of treatment. All patients in whom treatment failed or who
died had extensive bilateral pulmonary disease. In a multiple Cox proportional-hazards
regression model, the predictors of the time to treatment failure or death were a low
hematocrit (hazard ratio, 4.09; 95 percent confidence interval, 1.35 to 12.36) and a low
body-mass index (hazard ratio, 3.23; 95 percent confidence interval, 0.90 to 11.53). In-
clusion of pyrazinamide and ethambutol in the regimen (when susceptibility was con-
firmed) was associated with a favorable outcome (hazard ratio for treatment failure or
death, 0.30; 95 percent confidence interval, 0.11 to 0.83).
 
conclusions
 
Community-based outpatient treatment of multidrug-resistant tuberculosis can yield
high cure rates even in resource-poor settings. Early initiation of appropriate therapy
can preserve susceptibility to first-line drugs and improve treatment outcomes.
abstract
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n peru, multidrug-resistant tuber-
 
culosis, defined as disease caused by strains
of 
 
Mycobacterium tuberculosis
 
 that are resistant
to at least isoniazid and rifampin, is responsible for
about 3 percent
 
1,2
 
 of cases among patients not pre-
viously treated for tuberculosis and about 15 per-
cent of cases among those previously treated. It has
frequently been suggested that the comprehensive
“DOTS” strategy — which involves giving a short
course of directly observed multidrug treatment, as
well as requiring government commitment, case
detection by smear microscopy, a regular supply of
antituberculosis drugs, and standardized recording
and reporting — can eliminate multidrug-resistant
tuberculosis.
 
3-5
 
 However, the short-course chemo-
therapy on which DOTS is based usually fails to
cure multidrug-resistant tuberculosis.
 
6-8
 
 Rates of
cure of multidrug-resistant tuberculosis with stand-
ardized short-course chemotherapy range from
5 percent
 
9
 
 to 60 percent.
 
10
 
Therapy for multidrug-resistant tuberculosis
has been virtually nonexistent in poor countries. It
has been argued that drug-susceptibility testing and
second-line drugs are not cost effective in these
countries because of limited resources and that in-
tensive clinical management is impossible because
of lack of infrastructure.
 
3,11,12
 
 There are few treat-
ment models, and the reported rates of success of
treatment of multidrug-resistant tuberculosis in
middle-income countries and regions ranged in re-
cent reports from less than 60 percent in Indonesia
and Taiwan
 
13,14
 
 to just over 80 percent in Hong
Kong, Korea, and Turkey.
 
15-17
 
 In these studies,
treatment of multidrug-resistant tuberculosis was
costly and was provided in referral hospitals. The
few studies of the treatment of multidrug-resistant
tuberculosis in outpatients all found successful out-
comes in less than half of cases.
 
18-20
 
Without treatment, multidrug-resistant strains
can spread rapidly within vulnerable popula-
tions.
 
21-23
 
 Because standardized short-course che-
motherapy for multidrug-resistant tuberculosis has
been associated with unacceptably high rates of fail-
ure and relapse,
 
6,10,24 
 
new approaches to treatment
in poor countries are needed.
 
25-27
 
 We conducted a
community-based project for the treatment of mul-
tidrug-resistant tuberculosis in a resource-poor
setting. This DOTS-Plus project — which entailed
the addition of second-line drugs, monitoring by
sputum culture, drug-susceptibility testing, and di-
rectly observed individualized therapy
 
28
 
 to the well-
established Peruvian DOTS program — treated a
cohort of patients with long-standing disease due
to highly resistant strains of 
 
M. tuberculosis.
 
29,30 
 
We
identified risk factors associated with poor out-
comes and predictors of the time to death.
 
study patients
 
Between August 1, 1996, and November 30, 1998,
731 patients were referred for evaluation for multi-
drug-resistant tuberculosis by Socios En Salud, a
nongovernmental organization working in north-
ern Lima, Peru, in collaboration with the Peruvian
Ministry of Health and academic and nongovern-
mental organizations based in the United States.
Seventy-five (10 percent) met the following criteria
for inclusion in the study: beginning of supervised,
individualized treatment for multidrug-resistant
tuberculosis before February 1, 1999; residence in
the government-approved catchment area in north-
ern Lima (Carabayllo, Comas, and Independencia
districts); referral by a collaborating health center
after the failure of at least one course of directly ob-
served, standardized short-course chemotherapy;
laboratory-documented multidrug-resistant tuber-
culosis; survival until the results of drug-suscepti-
bility testing became available; and provision of
written informed consent. All 75 patients who be-
gan therapy during this period are included in this
report; high-grade drug resistance, gravity of dis-
ease, and the presence of coexisting conditions were
not indications for exclusion. Most patients referred
did not live in the catchment area.
 
bacteriologic studies 
and drug-susceptibility testing
 
Sputum samples were collected for smear micros-
copy and culture at base line and monthly thereaf-
ter. The samples were processed and read according
to international standards
 
31
 
 at Sergio E. Bernales
Hospital in Lima. At base line, isolates of 
 
M. tuber-
culosis
 
 were tested for susceptibility to the following
drugs: isoniazid (concentrations, 0.2, 1, and 5 µg
per milliliter), rifampin (1 µg per milliliter), etham-
butol (5 µg per milliliter), pyrazinamide (100 µg per
milliliter), streptomycin (2 and 10 µg per milliliter),
kanamycin (5 µg per milliliter), capreomycin (10 µg
per milliliter), ethionamide (5 µg per milliliter), cy-
closerine (30 µg per milliliter), and ciprofloxacin
(2 µg per milliliter). Testing was performed by staff
i
methods
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members of the Massachusetts State Laboratory
Institute, using the proportion method
 
32
 
 on 7H10
agar plates and, for pyrazinamide, the BACTEC
 
33
 
method. Highly resistant isolates were tested on
7H9 agar plates for susceptibility to amikacin (2, 4,
and 8 µg per milliliter), rifabutin (0.12, 0.5, and 2 µg
per milliliter), and clarithromycin (2, 8, and 32 µg
per milliliter) at the National Jewish Medical and
Research Center in Denver.
 
treatment and monitoring 
of adverse events
 
While the results of susceptibility testing were pend-
ing, most patients were treated empirically under
direct observation with regimens containing at least
five drugs to which their strains were deemed likely
to be sensitive on the basis of previous regimens
used. The definitive regimens, containing a mini-
mum of five drugs and lasting at least 18 months,
were determined on the basis of the results of drug-
susceptibility tests, which were available a mean
(±SD) of 62.6±32.9 days after sputum collection.
First-line drugs were used preferentially even in cas-
es in which repeated test results were inconsistent,
provided that susceptibility had been documented
at least once. A parenteral agent was administered
for at least six months after culture conversion.
 
34
 
Treatment was terminated after 12 or more consec-
utive negative cultures had been recorded. Sputum
samples continued to be collected and cultured at
least annually after the completion of treatment.
Patients received limited nutritional, financial, and
social support through Socios En Salud.
 
35
 
Treatment was given on an outpatient basis.
Treatment and surveillance for adverse events were
managed by a team of specially trained community
health workers, nurses, and physicians under the
auspices of Socios En Salud.
 
29,30
 
 Each patient un-
derwent complete clinical — including neurologic,
psychiatric, and audiometric — evaluations before
enrollment. Base-line laboratory analyses includ-
ed a complete blood count, measurement of blood
urea nitrogen and serum creatinine, tests of hepatic
function (measurement of serum aminotransfer-
ases, bilirubin, and alkaline phosphatase), enzyme-
linked immunosorbent assay for the human immu-
nodeficiency virus (HIV), and a Venereal Disease
Research Laboratory test at base line. Monitoring
of renal and hepatic function was performed regu-
larly during therapy; other laboratory tests were per-
formed as indicated, on the basis of symptoms.
 
definitions of outcome
 
Probable cure was defined by at least 12 months of
consecutive negative cultures during therapy; a sin-
gle intervening positive culture with fewer than 10
colonies was allowed. Treatment failure was defined
by the presence of a positive culture after six months
of treatment. Withdrawal from therapy was defined
by one or more months of missed therapy during
the first year, and two or more months missed dur-
ing the second year. Death was defined as death
from any cause during therapy or follow-up. Relapse
was defined by two or more positive cultures after
the completion of treatment among patients whose
treatment outcome was probable cure.
 
collection of data
 
Patients’ characteristics and risk factors at base line
(drawn from clinical records with the use of a struc-
tured instrument) included the following: extent of
pulmonary parenchymal damage; number of pre-
vious treatments; low body-mass index (the weight
in kilograms divided by the square of the height in
meters), defined as less than 18.5 for women and
less than 20 for men
 
36
 
; anemia, defined as a hema-
tocrit of less than 30 percent in women or less than
36 percent in men
 
37
 
; the number of antituberculo-
sis agents to which the infecting strain was resist-
ant; the number of drugs in the regimen; age; sex;
household size; history of homelessness, substance
abuse, or institutionalization; medical history and
coexisting conditions; respiratory difficulty, observed
as tachypnea at rest (more than 26 breaths per min-
ute),
 
38
 
 dyspnea at rest or on exertion, or use of ac-
cessory muscles; and the time elapsed since the first
diagnosis of tuberculosis and multidrug-resistant
tuberculosis.
 
statistical analysis
 
Statistical analyses were performed to determine the
associations between risk factors and a poor out-
come (treatment failure or death) during therapy
and the follow-up period, through August 31, 2002.
Clinically relevant risk factors were analyzed with
the use of Kaplan–Meier estimates and Cox propor-
tional-hazards models to generate estimates of the
associations with the time to death or treatment
failure. Confounding by demographic characteris-
tics, previous treatment history, and resistance to
first-line drugs was assessed by multiple Cox pro-
portional-hazards models. Plots of the natural log-
arithm of the negative of the natural logarithm of
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the survival curves for all levels of primary predictors
were consistent with the assumption of proportion-
ality.
 
39
 
 Data on patients who withdrew from therapy
were censored at the time of withdrawal, since their
risk of a poor clinical outcome could no longer be
assessed.
 
40
 
Data were entered into Access97 (Microsoft).
Data were missing for some patients for some risk
factors; missing values for body-mass index and
hematocrit were imputed as the sex-specific medi-
ans. SAS software (version 8.1) was used for all
analyses. All reported P values are two-sided.
 
base-line demographic 
and clinical characteristics
 
The patients were young, and most were single
(Table 1), with nearly equal numbers of men and
women. The household size was generally large,
and often two or more patients came from a single
household. More than half the patients had prior
or current medical illness; four had concurrent ex-
trapulmonary tuberculosis. One of 65 patients test-
ed had HIV infection. A low hematocrit was record-
ed in 12 patients (18 percent). Nearly half the
patients had an elevated resting respiratory rate, a
low body-mass index, or both. Bilateral cavitary pa-
renchymal disease was evident in 47 base-line chest
radiographs (63 percent). The patients had received
treatment with a median of 3 prior antituberculosis
regimens (range, 0 to 8) during the nearly four years
between the diagnosis of tuberculosis and the initi-
ation of the individualized regimens described here.
The patients had been previously exposed to a me-
dian of 7 antituberculosis drugs (range, 0 to 10) for
at least one month each. The infecting strains of
 
M. tuberculosis
 
 were resistant to a median of 6 drugs
(range, 2 to 12).
 
outcomes
 
The 75 patients received treatment with 58 differ-
ent regimens (Fig. 1), containing a median of six
drugs (range, five to nine) (Table 2) and lasting a
median of 23 months (range, 0.4 to 35.9). The rec-
ords of 60 patients were reviewed systematically for
adverse events; 44 patients (73 percent) had such
events, and all events were managed without physi-
cian-directed discontinuation of therapy.
 
41
 
Sixty-six patients completed four or more months
of therapy; conversion was evident in smears and
cultures in a median of just over one month. Of these
66 patients, 55 (83 percent) had probable cures at
the completion of therapy, 5 patients (8 percent)
withdrew from therapy, therapy failed in 1 patient,
and 5 patients (8 percent) died while receiving ther-
apy, after having completed more than four months
of therapy.
Patients were followed for a median of 40
months (range, 7 to 66) after therapy. During thera-
py and follow-up, 18 poor clinical outcomes oc-
curred: 17 deaths and 1 failure of therapy. Autopsies
were not performed; the causes of death, as suggest-
ed by the clinical history, are shown in Table 3.
 
predictors of a poor clinical outcome
 
In univariate analyses, a low hematocrit was found
to predict a poor outcome throughout therapy and
follow-up: after four months of therapy, only four
patients with a normal base-line hematocrit value
(6 percent) had died, whereas five patients with a
low hematocrit (42 percent) had died (P<0.001 by
the generalized Wilcoxon test). Low base-line body-
mass index was also predictive of earlier death: at
four months, only one patient with normal base-
line body-mass index (2 percent) and eight patients
with low body-mass index (25 percent) had died
(P<0.001 by the generalized Wilcoxon test).
In the final multiple Cox proportional-hazards
regression model, a low hematocrit (P=0.01 by the
Wald 
 
x
 
2
 
 test) and resistance to pyrazinamide or
ethambutol (P=0.02 by the Wald 
 
x
 
2
 
 test) were sig-
nificantly associated with the time to a poor out-
come (Table 4). Although low body-mass index was
of borderline statistical significance in this model
(P=0.07 by the Wald 
 
x
 
2
 
 test), it confounded the ef-
fect of a low hematocrit, lowering the effect esti-
mate by more than 30 percent. After adjustment
for low body-mass index and low hematocrit, nul-
liparous women were at greater risk for a shorter
time to a poor outcome than other women (P=0.01
by the Wald 
 
x
 
2
 
 test).
Large-scale, standardized surveys have revealed the
presence of patients with multidrug-resistant pul-
monary tuberculosis in virtually every country stud-
ied, yet to date, specific therapy for this disease has
been restricted to high- and middle-income coun-
tries where care is usually delivered within special-
ized referral centers. This project in Peru yielded
more probable cures than expected in patients
whose prognosis was poor because of chronic,
results
discussion
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* Data on some of the characteristics were missing for some patients. Data on household size were available for 69 patients; on 
marital status, for 71; on parity, for the 38 women; on hematocrit, for 68 patients; on respiratory difficulty, for 65; on respiratory 
rate, for 29; and on body-mass index, for 69.
† Observed respiratory difficulty was defined as dyspnea, use of accessory muscles, or elevated resting respiratory rate.
‡ Previous or current coexisting conditions included psychiatric illness (28 patients), hepatitis (3 patients), human immunodeficiency 
virus infection (1 patient), hypothyroidism (1 patient), diabetes (1 patient), epilepsy (1 patient), malnutrition (15 patients), anemia 
(12 patients), gastritis (10 patients), and aortic stenosis (1 patient).
§ The drugs tested were isoniazid, pyrazinamide, rifampin, ethambutol, streptomycin, kanamycin, capreomycin, ciprofloxacin, ethi-
onamide, and cycloserine; when clinically indicated, amikacin, rifabutin, and clarithromycin were also tested. The first-line drugs 
were isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. The second-line drugs were kanamycin, capreomycin, 
ciprofloxacin (or other fluoroquinolones), ethionamide, cycloserine, amikacin, rifabutin, and clarithromycin. The parenteral 
 
drugs were streptomycin, kanamycin, capreomycin, and amikacin.
 
Table 1. Characteristics of the 75 Patients at the Initiation of Individualized Treatment Regimens.
Characteristic* No. of Patients (%) Median (Range)
 
Sex
Male
Female
37 (49)
38 (51)
Age (yr) 26.8 (11.8–65.1)
Household size (no. of members) 7 (2–20)
Marital status
Unmarried (single, widowed, separated, or divorced)
Married
47 (66)
24 (34)
Parity
0 live births
≥1 live births
23 (61)
15 (39)
0 (0–9)
Hematocrit (%)
Men
Women
Men with hematocrit <36%
Women with hematocrit <30%
7 (23)
5 (14)
36.5 (21–51)
41 (21–48)
34 (24–51)
Observed respiratory difficulty†
Any
None
32 (49)
33 (51)
Resting respiratory rate
>26 breaths/min
≤26 breaths/min
13 (45)
16 (55)
25 (15–40)
Body-mass index
Men
Women
Men with body-mass index <20
Women with body-mass index <18.5
15 (41)
17 (45)
19.9 (12.4–29.8)
20.6 (13.1–29.8)
19.0 (12.4–25.2)
Previous or current coexisting condition‡
Any
None
40 (53)
35 (47)
History of homelessness, imprisonment, other institutionalization, or addiction 
to drugs or alcohol
17 (23)
Months from first diagnosis of tuberculosis to individualized treatment regimen 44.2 (2.1–383.4)
Months from first diagnosis of multidrug-resistant tuberculosis to individual-
ized treatment regimen
8.1 (0.2–103.2)
No. of drugs to which 
 
M. tuberculosis
 
 strain was resistant at initiation of treatment§
All drugs
First-line drugs
Second-line drugs
Parenteral drugs
6 (2–12)
5 (2–5)
1 (0–7)
1 (0–4)
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highly resistant tuberculosis, extensive parenchy-
mal damage, and previous exposure to repeated,
standardized regimens that probably resulted in
the amplification of drug resistance. The percent-
age with probable cures in our community-based,
ambulatory program (83 percent) was as high as
any reported in a hospital setting to date.
The seminal report on the treatment of severe
multidrug-resistant tuberculosis in a referral hos-
pital in the United States documented a favorable
response in 65 percent of patients.
 
42
 
 In reports
from middle-income countries or regions, the per-
centages responding favorably ranged from 50 per-
cent in Taiwan
 
14
 
 to more than 80 percent in Hong
Kong,
 
15
 
 Korea,
 
16
 
 and Turkey.
 
17
 
 The only compari-
sons to date of studies among outpatients are from
Florida, in which only 48 percent of patients com-
pleted treatment,
 
19
 
 and Korea and Peru (a study us-
ing the Peruvian National Tuberculosis Program
standardized regimen), in which 48 percent were
cured.
 
18,20
 
The encouraging outcomes in Lima are proba-
 
Figure 1. Frequency Distribution of Antituberculosis Agents Received by the 75 Patients as Part of Individualized Treat-
ment Regimens.
 
All patients were infected with strains that were resistant to at least low-dose isoniazid (critical concentration, 0.2 µg per 
milliliter) and rifampin. High-dose isoniazid (900 mg twice weekly) was given to patients whose infecting strains had in 
vitro susceptibility to high-dose isoniazid (critical concentration, 5.0 µg per milliliter). The fluoroquinolones used were 
ciprofloxacin and ofloxacin.
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* Data on time to conversion were available for the 66 patients who completed 
at least four months of therapy. For all other variables, data were available for all 
 
75 patients.
 
Table 2. Characteristics of Treatment Regimens.*
Characteristic No. (%)
Median
(Range)
 
No. of drugs per patient in individualized treatment 
regimen
First-line drugs
Second-line drugs
Parenteral drugs 
6 (5–9)
1 (0–4)
5 (2–7)
1 (1–2)
Receipt of regimen containing ethambutol 
or pyrazinamide
Regimen containing ethambutol
and pyrazinamide
Regimen containing ethambutol only
Regimen containing pyrazinamide only
Regimen containing neither drug
6 (8)
7 (9)
20 (27)
42 (56)
Time to conversion — days
Smear
Culture
38 (14–264)
35 (23–181)
Duration of therapy — mo 23 (0.4–35.9)
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bly due to several factors, some unique to our study
population and others to the treatment program.
Although our patients had been sick for longer and
had higher-grade resistance than those in other co-
horts, they were generally younger, with fewer se-
rious coexisting conditions. Unlike the cohorts in
Korea and Florida, which had high default rates,
 
18,19
 
all patients in our cohort received directly observed
therapy. Adverse effects, moreover, were carefully
managed to ensure completion of treatment: only
one patient withdrew from therapy because of ad-
verse events.
 
41
 
Therapy was more aggressive than in other stud-
ies; patients were treated with more drugs and at
higher doses for longer periods.
 
13,41,43
 
 It is likely
that this protocol mitigated, to some degree, the
effect of high-grade resistance. In other cohorts,
such resistance has increased the likelihood of treat-
ment failure.
 
42,44,45 
 
Furthermore, the use of indi-
vidualized regimens permitted patients to receive
treatment with maximally effective drug combina-
tions to which the strains had documented in vitro
susceptibility, thus reducing the risk of further am-
plification of resistance.
 
46,47
 
 More than 70 percent
of the patients with strains resistant to all five first-
line drugs had probable cures at the completion of
treatment.
Our results suggest that shortening the time to
the initiation of appropriate therapy will further im-
prove outcomes and reduce costs in a number of
ways. Most important, in a setting with high cure
rates with first-line treatment, patients in whom di-
rectly observed, short-course regimens have failed
and patients thought to have primary multidrug-
resistant tuberculosis are unlikely to benefit from
the standardized retreatment regimens recommend-
ed for resource-poor settings.
 
48
 
 Additional courses
of therapy based on isoniazid and rifampin are like-
ly to lead to increased parenchymal damage and
amplified resistance to the other first-line drugs.
 
6
 
In fact, in a preliminary analysis from a larger co-
hort of patients in Lima, resistance to streptomycin,
pyrazinamide, and ethambutol was three times as
likely in strains collected from patients who had
been treated with two or more previous regimens
as in those who had received no treatment or treat-
ment with only one regimen.
 
49
 
The treatment of patients with strains resistant
to four or five first-line drugs is more difficult and
more expensive than the treatment of those whose
strains are sensitive to one or more of these agents.
We found that patients with strains resistant to pyr-
azinamide and ethambutol were more likely to have
poor outcomes. Moreover, the resistance pattern
was the greatest determinant of the cost of therapy
in this cohort, with costs per patient ranging from
$504 to $32,383. At a mean of $15,681 per patient,
these costs were low — approximately 10 percent
of those for hospitalized patients
 
50,51
 
 — but well
beyond the reach of most national tuberculosis
programs. Advocacy work and pooled procurement
have since resulted in dramatic decreases in the
costs of second-line antituberculosis drugs.
 
52
 
 Now
such patients can be treated for approximately half
the earlier cost; preserved susceptibility to pyrazin-
amide and ethambutol further reduces the expense.
The association between signs of severe, pro-
tracted disease — elevated resting respiratory rate,
bilateral involvement, low body-mass index, and
anemia — and poor outcome is not unexpected
and further underscores the importance of early
referral for appropriate therapy.
 
53-55
 
 Aggressive
adjuvant interventions (blood transfusion, hyper-
alimentation, and supplemental oxygen) may be
important for reducing mortality among chroni-
cally ill patients. Even if these costly therapies prove
beneficial, however, referring patients to appro-
priate therapy before they have manifestations of
chronic disease would save both lives and resourc-
es. It would also reduce rates of transmission. In-
adequately treated patients often remain infectious,
transmitting multidrug-resistant strains to house-
hold members and health care workers. 
The poorer outcomes for women, although not
fully explained by the data available for this popula-
tion, are consistent with the elevated risk of progres-
 
Table 3. Suspected Causes of Death among Patients Who Died
during or after Individualized Treatment.
Cause During Therapy After Completion of Therapy
 
<4 mo 
Completed
≥4 mo
Completed
Massive hemoptysis 3 0 0
Respiratory failure 5 2 1 (14 wk after completion)
Sepsis (multisystem organ 
failure)
0 1 0
Relapse or reinfection with 
multidrug-resistant 
tuberculosis
0 0 1 (23 wk after completion)
Probable narcotic overdose 0 0 1 (43 wk after completion)
Unknown 1 2
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sion from infection to disease, increased mortality,
and higher incidence of extrapulmonary disease
among women with tuberculosis in many parts of
the world.
 
56-58
 
 Our finding that young, childless
women were less likely to respond to therapy may
point to the important role of adult children, who
often provided substantial support to their moth-
ers. It is also possible that the long-standing dis-
ease afflicting young women in northern Lima was
so debilitating as to have precluded reproduction
for physiological and social reasons.
Our experience establishes that patients with
chronic multidrug-resistant tuberculosis can be
treated successfully as outpatients outside referral
centers and in a resource-poor country. The DOTS-
Plus model relies on community health workers su-
pervised by nurses working in close collaboration
with the country’s successful National Tuberculosis
 
* CI denotes confidence interval. Both univariate and multivariate analyses were Cox proportional-hazards regression analyses.
† P values were derived by the Wald 
 
x
 
2
 
 test.
‡ P<0.05 by the Wald 
 
x
 
2
 
 test.
§ The multivariate model included low hematocrit, low body-mass index, and the combined predictor for pyrazinamide and 
ethambutol.
¶ The resting respiratory rate was not included in the multiple logistic-regression models because of the large number of missing 
values.
¿ Exclusion of these drugs was predicated on definitive evidence of in vitro resistance. Inclusion in the regimen was based on at 
least one confirmation of susceptibility.
 
**Only women were included. The multivariate model was adjusted for anemia and low body-mass index.
 
Table 4. Risk Factors Associated with the Time to a Poor Outcome during Therapy.*
Risk Factor
Patients with
Poor Outcomes Univariate Analysis
Multivariate
Analysis
 
Crude
Hazard Ratio
(95% CI)
P
Value†
Adjusted
Hazard Ratio
(95% CI)
no./total no.
Sex
Female
Male
12/38
6/37
2.14 (0.80–5.71) 0.13 —
Age
>26.8 yr
≤26.8 yr
7/37
11/38
1.40 (0.54–3.65) 0.49 —
Body-mass index
Low
Normal
14/32
4/43
5.13 (1.68–15.69)‡ 0.004 3.23 (0.90–11.53)§
Hematocrit
Low
Normal
8/12
10/63
5.17 (2.03–13.17)‡ <0.001 4.09 (1.35–12.36)‡§
Radiographic findings
Bilateral disease and cavitary lesions
Bilateral disease only
Neither bilateral disease nor cavitary lesions
14/50
4/21
0/4
1.77 (0.64–4.64) 0.28 —
Resting respiratory rate¶
>26 breaths/min
≤26 breaths/min
1/16
7/13
10.32 (1.27–84.04)‡ 0.03 —
Pyrazinamide and ethambutol in regimen¿
Neither
Either
Both
13/42
5/27
0/6
0.47 (0.19–1.18) 0.11 0.30 (0.11–0.83)‡§
Parity**
0 live births
≥1 live births
9/23
3/15
3.87 (0.82–18.21) 0.09 7.48 (1.50–37.34)‡
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Program. By moving treatment into the communi-
ty, it is possible, without compromising the quality
of therapy, to lower costs and reduce the risk of
nosocomial spread of multidrug-resistant tubercu-
losis.
 
59-61
 
 During the past two years, we have ex-
panded the DOTS-Plus model to cover much of Li-
ma. The costs of therapy have continued to drop
even as control over the distribution of second-line
drugs has been enhanced. Successful community-
based therapy for multidrug-resistant tuberculosis
— and potentially for HIV
 
62,63
 
 — provides hope for
the tens of millions of patients who are suffering
from chronic infectious diseases in settings with
limited health infrastructure.
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